IL-IFT
9.5.2023 14:01:28 CEST | Business Wire | Press release
The Institute of Food Technologists (IFT), a nonprofit scientific organization committed to advancing the science of food and its application across the global food system, and the Seeding The Future Foundation are proud to announce the return of the annual Seeding The Future Global Food System Challenge. The Challenges invites scientists, engineers, innovators, entrepreneurs, and multidisciplinary teams from non-governmental organizations (NGOs), non-profits, social enterprises, universities, research institutions as well as small and emerging startups to submit their game-changing innovations that will help transform the global food system.
Now in its third year, the Challenge will once again award $1 million in grants and prizes via Seed Grants ($25,000 each), Growth Grants ($100,000 each), and Seeding The Future Grand Prizes ($250,000 each). Last year’s Growth Grant and Grand Prize winners included:
- Commercializing black soldier fly larvae as chicken feed to enhance egg nutrition and lower the cost of eggs in Rwanda. (Food Systems for the Future)
- Eliminating dangerous aflatoxins from smallholder supply chains starting with peanuts in Haiti. (Acceso)
- Accelerating the deployment of aquaponics that combine soilless crop production and fish farming to increase global food production in the face of climate change. (INMED Partnerships for Children)
- Community-led solar powered cold storage program to enable access to improved agricultural techniques and practices in rural developments. (Smart Villages Resource Group)
- Leveraging the US Postal Service to bring fresh produce from farms to front doors. (World Wildlife Fund)
“The Global Food System Challenge is meant to be a call to action to the global food community. More than 840 million people suffer from chronic hunger, severe undernutrition, and extreme poverty while more than 30% of food is wasted globally every year. Climate change, conflicts and poverty prevent equitable access to safe and nutritious food for many populations in both developed and developing regions. We urgently need impactful and transformative innovations that will lead to a sustainable food system and enable access of healthy, affordable, and appealing food that consumers trust,” said Bernhard van Lengerich, founder of Seeding The Future Foundation.
While application submissions open on June 1 and close on August 1, interested participants can review guidelines here to begin preparing their submission.
Since 2021, more than 1,500 submissions from 75 countries have been received from multidisciplinary teams from academic and research institutions, non-profits, and startups. The Challenge is funded by the Seeding The Future Foundation and hosted by IFT.
“The Seeding The Future Global Food System Challenge mirrors IFT’s mission and commitment to addressing food insecurity and ensuring a healthy future for our global food supply,” said IFT CEO Christie Tarantino-Dean. “We are thrilled to be partnering once again with Bernhard and the Seeding The Future Foundation on one of the most important showcases of food innovation and ingenuity.”
For more information, visit ift.org/food-system-challenge. Applicants needing additional support are encouraged to review Frequently Asked Questions.
About Institute of Food Technologists
The Institute of Food Technologists (IFT) is a global organization of approximately 12,000 individual members from more than 100 countries committed to advancing the science of food. Since 1939, IFT has brought together the brightest minds in food science, technology and related professions from academia, government, and industry to solve the world’s greatest food challenges. IFT works to ensure that its members have the resources they need to learn, grow and advance the science of food as the population and the world evolve. IFT believes that science is essential to ensuring a global food supply that is sustainable, safe, nutritious, and accessible to all. For more information, please visit ift.org.
About Seeding The Future Foundation
The Seeding The Future Foundation is a private, non-profit organization motivated by its core value that everyone should always have equitable access to safe, nutritious, affordable, appealing, and trusted food. It seeks to inspire innovative solutions that can help transform the global food system to be more sustainable and benefit the health of people and the environment. The Foundation provides seed funding and support to promising ideas and high impact innovations to improve food systems globally, technologies to reduce post-harvest losses in developing regions, as well as foundational work in academia and research. For more information, please visit seedingthefuture.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005101/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
